m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02432)
Name
Meloxicam
Synonyms
Meloxicam (SoluMatrix/arthritis); Meloxicam nanoformulation capsules (arthritis), iCeutica; Meloxicam (SoluMatrix/arthritis), iCeutica
    Click to Show/Hide
Status
Approved
Structure
Formula
C14H13N3O4S2
InChI
1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,18H,1-2H3,(H,15,16,19)
InChIKey
ZRVUJXDFFKFLMG-UHFFFAOYSA-N
PubChem CID
54677470
TTD Drug ID
D0G7FJ
INTEDE Drug ID
DR1020
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Cytochrome P450 2C8 (CYP2C8)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Meloxicam. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Meloxicam through regulating the expression of Cytochrome P450 2C8 (CYP2C8). [1], [2]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Meloxicam. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Meloxicam through regulating the expression of Cytochrome P450 2C8 (CYP2C8). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Meloxicam. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Meloxicam through regulating the expression of Cytochrome P450 2C8 (CYP2C8). [1], [2]
YTH domain-containing protein 2 (YTHDC2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Meloxicam. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Meloxicam through regulating the expression of Cytochrome P450 2C8 (CYP2C8). [1], [2]
Prostaglandin G/H synthase 2 (COX-2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Meloxicam. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Meloxicam through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). [3], [4]
References
Ref 1 Methylation of adenosine at the N(6) position post-transcriptionally regulates hepatic P450s expression. Biochem Pharmacol. 2020 Jan;171:113697. doi: 10.1016/j.bcp.2019.113697. Epub 2019 Nov 7.
Ref 2 Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?. Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):607-20. doi: 10.1517/17425250902970998.
Ref 3 METTL3 promotes experimental osteoarthritis development by regulating inflammatory response and apoptosis in chondrocyte. Biochem Biophys Res Commun. 2019 Aug 13;516(1):22-27. doi: 10.1016/j.bbrc.2019.05.168. Epub 2019 Jun 8.
Ref 4 Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1)(Pt 1):247-51. doi: 10.1042/bj3060247.